Stay updated on Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial
Sign up to get notified when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.

Latest updates to the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page
- Check4 days agoChange DetectedThe two screenshots depict the same study details page with no substantive differences in core content, such as the study overview, eligibility criteria, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check11 days agoNo Change Detected
- Check32 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference3%

- Check39 days agoChange DetectedUpdate to version v3.1.0; removal of several MedlinePlus topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) and archival of v3.0.2.SummaryDifference0.4%

- Check54 days agoChange DetectedThe page revision was updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.2%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check68 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations, as well as the introduction of terms related to drug safety and counterfeit drugs. Notably, the previous version's references to certain drug names and conditions have been removed.SummaryDifference7%

Stay in the know with updates to Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.